Clinical trial · Observational
Predictive Biomarkers for IGF1R Targeted Therapy in Ovarian Cancer
NCT02711865CI-TRIAL-00021414unknownClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The main goal of this study is to employ a novel proteomic approach to identify predictive tumor biomarkers that will increase the efficacy of insulin-like growth factor (IGF1R) targeted therapy in epithelial ovarian cancer. It is expected that these predictive biomarkers will be applied to increase the response rate in selected groups of patients.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Ovarian Cancer | Malignant Ovarian Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| IGF1R antibody MK0646 | Biological | — | UNRESOLVED |
| Saline solution | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- MK-0646
- description
- Tumor specimens removed from 20 women with ovarian cancer are injected into 40 mice treated with the IGF1R antibody MK-0646. The drug will be administered twice weekly, via IP injection at a dose of 500 microgram per animal.
- interventionNames
- Biological: IGF1R antibody MK0646
- label
- Control
- description
- Tumor specimens removed from 20 women with ovarian cancer are injected into 40 mice who receive no other treatment.
- interventionNames
- Other: Saline solution
Primary outcomes (1)
- measure
- Responsive to IGF1R therapy
- timeFrame
- One year
- description
- Mean tumor volume will be calculated and growth inhibition will be reported as the percentage decrease of tumor volume compared with the control.
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Patients with ovarian cancer Exclusion Criteria: * All others
References
Publications (0)
Data not yet available
No reference posted for this study.